Correspondence

Advice on the anticonvulsant drugs Pregabalin and Gabapentin

The chair of the Advisory Council on the Misuse of Drugs writes to Karen Bradley about Pregabalin and Gabapentin.

• From: Advisory Council on the Misuse of Drugs
• Published: 14 January 2016
• Last updated: 17 October 2018 — See all updates

Documents

ACMD advice on Pregabalin and Gabapentin

PDF, 67 KB, 7 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Addendum to advice on the anticonvulsant drugs Pregabalin and Gabapentin, October 2018

HTML

Details

Les Iversen, chair of the ACMD, writes to Karen Bradley, Minister for Preventing Abuse and Exploitation, recommending that Pregabalin and Gabapentin be made class C controlled substances.

Read the consultation outcome for the proposal to schedule Pregabalin and Gabapentin under the Misuse of Drugs Regulations 2001 on the National Archives website.

Published 14 January 2016
Last updated 17 October 2018 + show all updates

1. 17 October 2018

   Addendum to section 6 of the advice published.

2. 14 January 2016

   First published.